Aclidiniumbromid forbedrer lungefunktion og reducerer åndenød hos patienter med KOL
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Long-acting bronchodilators are central for treatment of COPD. This short review provides an overview of studies evaluating the efficacy of aclidinium bromide, a long-acting anticholinergic bronchodilator, for the treatment of COPD. Twice-daily dosing of aclidinium leads to clinically important improvements in forced expiratory volume in 1 second, health status, use of rescue medication, day-time dyspnoea and exercise tolerance. The available studies also suggest an effect on night-time dyspnoea and exacerbation rate in patients with COPD. Aclidinium seems to have potential for a significant role in the future management of COPD.
Bidragets oversatte titel | Aclidinium bromide improves the lung function and reduces dyspnoea in patients with COPD. |
---|---|
Originalsprog | Dansk |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 176 |
Udgave nummer | 28 |
Sider (fra-til) | 1296-1299 |
Antal sider | 4 |
ISSN | 0041-5782 |
Status | Udgivet - 31 mar. 2014 |
ID: 137426804